‌

US Patent 7501122 Treatment with anti-ErbB2 antibody combinations

Patent 7501122 was granted and assigned to Genentech on March, 2009 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Current Assignee

Genentech

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

7501122

Date of Patent

March 10, 2009

Patent Application Number

11223361

Date Filed

September 9, 2005

Patent Citations Received

‌

US Patent 12128103 Adjuvant treatment of HER2-positive breast cancer

‌

US Patent 11655305 Treatment of metastatic breast cancer

‌

US Patent 11992529 Adjuvant treatment of HER2-positive breast cancer

‌

US Patent 12110341 Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof

‌

US Patent 11654105 Subcutaneous HER2 antibody formulations

Patent Primary Examiner

‌

Alana M. Harris

Patent abstract

The present application describes methods for treating ErbB-expressing cancer with anti-ErbB2 antibody combinations.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7501122 Treatment with anti-ErbB2 antibody combinations

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API